A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Breed method is a laboratory technique used for counting microorganisms in milk. It was introduced in 1910 by American biologists Samuel Cate Prescott and Robert Stanley Breed. It is a method for somatic cell count, to know the number of living and dead microorganisms. When the method only recounts living organisms is called "viable count". There are many methods for the quantification of microorganisms, including microscopy methods, Coulter counter, Mass Spectrometry (for estimating cell mass), and Cell Culture methods which form and grow colonies of bacteria. The existing security in dairy products is given by the microbiological quality of the same, which ensures consumption from the point of view of health. The analysis of the quality of raw milk is a common practice in the dairy industry and aims to control the quality of the samples and the material introduced into the processing plant, culminating in a mass-consumption to ensure quality standards. Somatic cell count
13. Ir Med J. 2026 Sep 28;119(8):160. Non-Arteritic Anterior Ischaemic Optic Neuropathy Associated with Semaglutide use. Kearney M, Smyth NM, Hassan HSA, Khan MS. PRESENTATION: Non-arteritic ischaemic optic neuropathy (NAION) is a common cause of acute, painless monocular visual disturbance in older adults. This case discusses a woman in her 70s with vascular risk factors who presented with a three-day history of progressive left sided visual disturbance. Examination demonstrated a left relative afferent pupillary defect and inferior quadrantopia. DIAGNOSIS: Haematological investigations and neuroimaging were unremarkable. Formal ophthalmological assessment demonstrated superior optic disc swelling with an inferior visual field defect, consistent with NAION. TREATMENT: The patient had been taking semaglutide, as prescribed, for the six months prior to presentation. This was identified as a potential contributory agent and was discontinued. Visual acuity partially improved following cessation of semaglutide. DISCUSSION: This case seeks to highlight a possible association between semaglutide use and NAION. Although causality remains unproven, it underscores the importance of pharmacovigilance when manging patients presenting with ophthalmological symptoms.
Biohazardous safety issues are identified with specified labels, signs and paragraphs established by the American National Standards Institute (ANSI). Today, ANSI Z535 standards for biohazards are used worldwide and should always be used appropriately within ANSI Z535 Hazardous Communications (HazCom) signage, labeling and paragraphs. The goal is to help workers rapidly identify the severity of a biohazard from a distance and through colour and design standardization. Biological hazard symbol design:
Abortive initiation, also known as abortive transcription, is an early process of genetic transcription in which RNA polymerase binds to a DNA promoter and enters into cycles of synthesis of short mRNA transcripts which are released before the transcription complex leaves the promoter. This process occurs in both eukaryotes and prokaryotes. Abortive initiation is typically studied in the T3 and T7 RNA polymerases in bacteriophages and in E. coli. Abortive initiation occurs prior to promoter clearance. RNA polymerase binds to promoter DNA to form an RNA polymerase-promoter closed complex RNA polymerase then unwinds one turn of DNA surrounding the transcription start site to yield an RNA polymerase-promoter open complex RNA polymerase enters into abortive cycles of synthesis and releases short RNA products (contains less than 10 nucleotides) RNA polymerase escapes the promoter and enters into the elongation step of transcription
The Hmd holoenzyme includes the protein homodimer as well as its associated iron-containing cofactor. Several species of methanogens have been characterized that express enzymes in the Hmd hydrogenase family. Between species the enzyme is found with differing numbers of sub-units and some minor amino acid sequence variations. The monomer is approximately 45,000 Da in mass, although this value varies from species to species. The enzymatic activity of the enzyme is lost upon exposure to sunlight or UV. Photolysis causes the release of an iron atom and two molecules of carbon monoxide. In the holoenzyme the Fe and CO molecules are found associated with a 542 Da cofactor.
Sources: en.wikipedia.org
AlphaKnot complements KnotProt, a database focused on experimentally determined protein structures and their topological features. KnotProt provides detailed descriptions of knots, slipknots, and related entanglements in experimentally characterized proteins, whereas AlphaKnot was developed primarily to examine the much larger population of structures generated by modern protein-structure prediction methods. AlphaKnot has been used to investigate the frequency and distribution of knots in protein families and to identify previously uncharacterized topological architectures. Large-scale analyses of AlphaFold structures have identified unusual knot types and proteins containing multiple knots, while comparison with experimentally determined structures has provided examples in which unusual predicted topologies were subsequently confirmed experimentally. The database can therefore be used both as a source of candidate knotted proteins for experimental investigation and as a computational tool for examining the relationship between protein sequence, structure, and topology.
AM function can be compared to another peptide called pro-adrenomedullin N-terminal 20 peptide (PAMP), which both originate from a common precursor leading to angiogenesis, vasodilation, and anti-inflammatory processes. These two peptides are expressed in the gastrointestinal (GI) tract at a mass level, serving as GI hormones controlling processes like insulin secretion and gastric emptying. Past studies reveal that AM and PAMP also impact gut microbiome composition by fostering the development of beneficial bacteria (i.e., Bifidobacterium and Lactobacillus) and diminishing detrimental microbes.
MT-ND6 is a gene of the mitochondrial genome coding for the NADH-ubiquinone oxidoreductase chain 6 protein (ND6). The ND6 protein is a subunit of NADH dehydrogenase (ubiquinone), which is located in the mitochondrial inner membrane and is the largest of the five complexes of the electron transport chain. Variations in the human MT-ND6 gene are associated with Leigh's syndrome, Leber's hereditary optic neuropathy (LHON) and dystonia.
DT56a has been described in scientific literature as a selective estrogen receptor modulator (SERM)-like compound. Experimental studies have suggested that DT56a may exert agonistic effects on estrogen receptors in bone and brain tissues, while demonstrating limited activity in uterine and breast tissues. Several studies have investigated DT56a in relation to menopausal symptoms and bone health. In vitro studies have also reported stimulation of osteoblast activity in cultured human bone cells. Published studies have additionally suggested that DT56a does not significantly affect circulating hormone levels or blood coagulation parameters. Selective estrogen receptor modulator
When the B cells get activated, class switching can occur. The class switching involves switch regions that made up of multiple copies of short repeats (GAGCT and TGGGG). These switches occur at the level of rearrangements of the DNA because there is a looping event that chops off the constant regions for IgM and IgD and form the IgG mRNAs. Any continuous looping occurrence will produce IgE or IgA mRNAs. In addition, cytokines are factors that have great effects on class switching of different classes of antibodies. Their interaction with B cells provides the appropriates signals needed for B cells differentiation and eventual class switching occurrence. For example, interleukin-4 induces the rearrangements of heavy chain immunoglobulin genes. That is IL- 4 induces the switching of Cμ to Cγ to Cκ
Sources: en.wikipedia.org
1. Int J Pharm Compd. 2026 Jul-Aug;30(4):329-336. Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards. Willis J(1), Vu N(2)(3). Author information: (1)University of Oklahoma College of Pharmacy. (2)ARL Bio Pharma, Oklahoma City, Oklahoma. Nvu@arlok.com. (3)University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma. Compounded peptides have quickly moved from a niche topic to a growing area of interest among patients and prescribers. These products are promoted for a wide range of uses, including tissue repair, inflammation, metabolic health, and healthy aging. This article examines the proposed uses of these peptides, the concerns raised during the review, and the practical implications for compounders. Copyright© by International Journal of Pharmaceutical Compounding, Inc.
Actin-binding proteins (also known as ABPs) are proteins that bind to actin. This may mean ability to bind actin monomers, or polymers, or both. Many actin-binding proteins, including α-actinin, β-spectrin, dystrophin, utrophin and fimbrin, do this through the actin-binding calponin homology domain. This is a list of actin-binding proteins in alphabetical order. 25kDa 25kDa ABP from aorta 30akDA 30bkDa 34kDA 45kDa 110 kD dimer ABP 110 kD (Drebrin) p53 p58gag p185neu p116rip a-actinin Abl ABLIM Actin-Interacting MAPKKK Ssk2p ABP120 ABP140 Abp1p ABP280 (Filamin) ABP50 (EF-1a) Acan 125 (Carmil) ActA Actibind Actin Actinfilin Actinogelin Actin-regulating kinases Actin-Related Proteins Actobindin Actolinkin Actopaxin Actophorin Acumentin (= L-plastin) Adducin ADF/Cofilin Adseverin (scinderin) Afadin AFAP-110 Affixin Aginactin AIP1 Aldolase Angiogenin Anillin Annexins Aplyronine Archvillin (isoform of Supervillin) Arginine kinase Arp2/3 complex Band 4.1 Band 4.9 (Dematin) b-actinin b-Cap73 Bifocal Bistramide A BPAG1 Brevin (Gelsolin)
5-HEDH is an NADPH dehydrogenase oxidoreductase enzyme. It transfers a hydrogen cation (or hydron) H+ from 5(S)-hydroxy (i.e. 5(S)-OH) residues of its fatty acid targets to nicotinamide adenine dinucleotide phosphate+ (NADP+) to form 5-oxo (i.e. 5-O=) counterparts of its targets plus reduced NADP+, i.e. NADPH. The reaction (where R indicates a long chain [14 or more carbons] fatty acid) is: NADP+ + 5(S)-hydroxy fatty acid (i.e. 5(S)-OH-R) ⇌ {\displaystyle \rightleftharpoons } NADPH + H+ + oxo fatty acid (i.e. 5-O=R) The reaction appears to follow a ping-pong mechanism. It is fully reversible, readily converting 5-oxo targets to their corresponding 5(S)-hydroxy counterparts. The direction of this reaction is dependent on the level of NADP+ relative to that of NADPH: The immediate metabolic precursor to 5(S)-HETE, 5(S)-hydroperoxy-6S,8Z,11Z,14Z-eicosatetraenoic acid 5(S)-HpETE, can be converted to 5-oxo-ETE in a non-enzymatic dehydration reaction or chemical lipid peroxidation reactions. The physiological occurrence and relevancy of these reaction pathways has not been ascertained.
An automated synthesis is very similar in procedure to performing a manual synthesis. The overseeing chemist decides on a target molecule then formulates the experimental plan, which is a sequential series of steps. Then, they collect the required equipment and execute the plan. The automated synthesis follows the same pathway, except that the computer devises and executes the experimental plan. However, human revision is usually still required to ensure the automated route is practical and there are no implicit steps or conditions missing from the proposed procedure. In organic synthesis, organic synthesis software is used to automate the process of identifying sequences of reactions or routes that can be used to synthesize organic compounds.
Sources: pubmed.ncbi.nlm.nih.gov
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.